<DOC>
	<DOCNO>NCT01140061</DOCNO>
	<brief_summary>This study evaluate incidence erythema local cutaneous irritation administration MK-0873 patch cream formulation healthy participant participant mild psoriasis . Part I Part II healthy participant initiate prior Part III psoriasis participant . The primary hypothesis study : 1 ) MK-0873 safe well tolerate healthy participant participant psoriasis 2 ) maximum plasma concentration MK-0873 &lt; 20 nM healthy participant participant psoriasis .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics MK-0873 Following Patch Application Healthy Participants Psoriasis Participants ( MK-0873-020 )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>MK 0873</mesh_term>
	<criteria>Part I , II III : Female participant reproductive potential must test negative pregnancy agree use two acceptable method birth control ; In good general health ; Nonsmoker ; Part III : Has diagnosis plaquetype psoriasis , lesion cover least 3 % total body surface area ; Part I , II III : Has history stroke , chronic seizure major neurological disease ; Has history cancer ; Is nurse mother ; Part III : Has nonplaque form psoriasis ; Has current druginduced psoriasis ; Has receive phototherapy , systemic medications/treatments , use topical medication could affect psoriasis ; Has use systemic immunosuppressant biologics within past 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>